| RheumNow - Rheumatology News & Information

Unknown content type

Minimal Disease Activity: The Goal in PsA

By MedPage Today | 26 Jul 2018

The majority of patients with psoriatic arthritis (PsA) who achieved a state of minimal disease activity (MDA) after 6 months of treatment with adalimumab (Humira) maintained that response through 24 months, a large observational study found.

[...]

Steroids vs. NSAIDs in Treating Acute Gout

By Jack Cush, MD | 25 Jul 2018

Gout, the ancient disease of kings is usually treated with the ancient (and costly) drug colchicine, often without consideration of nonsteroidal antiinflammatory drugs (NSAID) or corticosteroids. A recent metanalysis compared the NSAIDS and steroids and showed that both were equipotent in managing the pain of acute gout, but corticosteroids appear had a more favorable safety profile.

[...]

Consensus Guidelines for Methotrexate in Juvenile Idiopathic Arthritis

By Jack Cush, MD | 24 Jul 2018

A consensus panel was convened to develop consensus-based clinical and therapeutic recommendations for the use of methotrexate (MTX) in the management of Juvenile Idiopathic Arthritis (JIA) patients.

[...]

Erectile Dysfunction in Gout

By Jack Cush, MD | 24 Jul 2018

The Journal of Rheumatology reports a population-based study demonstrating that gout is associated with an increased risk of developing erectile dysfunction (ED) suggesting that hyperuricemia and inflammation may be independent risk factors for ED.

[...]

Predicting Autoimmune Progression in ANA+ Patients

By Jack Cush, MD | 23 Jul 2018

Positive tests results for antinuclear antibodies (ANAs) are frequently referred to rheumatology despite their poor predictive value, even in individuals who are ‘At Risk’ for autoimmune connective tissue diseases (AI-CTDs). A new study shows that combining ANA positive with interferon-stimulated gene expression increased the liklihood of progression to AI-CTD.

[...]

Baricitinib Effective in SLE Trial

By Jack Cush, MD | 20 Jul 2018

Dan Wallace and colleagues report in Lancet the results of a phase II study of the selective baricitinib, an oral selective Janus kinase (JAK1 and JAK2) inhibitor, in patients with systemic lupus erythematosus, demonstrating the efficacy and safety of JAK1/2 inhibition with baricitinib as a new potential oral therapy for SLE.

[...]

The RheumNow Week in Review – Cocoon Therapy? (7.20.18)

By Jack Cush, MD | 20 Jul 2018

Dr. Jack Cush reviews highlights from the news and social media on RheumNow.com in the past week.

Biomarker Combo Predicts TNF Inhibitor Responses

By Jack Cush, MD | 19 Jul 2018

Based on clinical trial data, patients starting tumour necrosis factor-alpha inhibitors (TNFi) have roughly a two-thirds chance of achieiving a good clinical response. French investigators have studied a series of potential biomarkers and surmised that the combination of baseline prealbumin, platelet factor 4 and S100A12 can predict a 78% response to TNFi in rheumatoid arthritis (RA) patients.

[...]

The Lung in RA: Little Progress

By MedPage Today | 19 Jul 2018

The progress that has been seen in the management of many aspects of rheumatoid arthritis (RA) has not been paralleled for the pulmonary disease that remains the second most common cause of death among these patients, an Australian expert reported here at the annual meeting of the Florida Society of Rheumatology.

[...]

Unsafe Practices with Ambien Use

By Jack Cush, MD | 18 Jul 2018

Ambien (zolpidem) is the most widely used prescription hypnotic sedative since its introduction in 1992 and is currently the fourth most frequently prescribed psychiatric drug (2013). Recent US Food and Drug Administration Drug Safety Communications suggest limitations on use to reduce adverse effects. A study of the Medical Expenditures Survey in 2015 revealed that over 3.8 million adults reported using one or more prescriptions for zolpidem.

[...]

Immunophysiology of the Gout Attack

By MedPage Today | 18 Jul 2018

Gout may be an ancient disease, with arthritis of the big toe having been described in Egypt in 2,600 BC, but only now are the underlying pathophysiologic events being elucidated and understood.

[...]

Ultrasound Tenosynovitis Predicts RA Development

By Jack Cush, MD | 17 Jul 2018

Musculoskeletal ultrasound (US) has become a more widely used tool in rheumatology clinical practice. This study of early inflammatory arthritis patients shows that US-defined digit flexor tenosynovitis was more predictive of subsequent rheumatoid arthritis than findings of ACPA positivity or US-defined joint synovitis.

[...]

‹ previous
…
3
4
5
6
7
8
9
10
11
…
next ›

Search form

Unknown content type